

2010 RESEARCH PUBLICATIONS

- Fronza JS, Bentrem DJ, **Baker MS, Talamonti MS, Ujiki MB**. Laparoscopic distal pancreatectomy using radiofrequency energy. *Am J Surg*. 2010 Mar;199(3):401-4; discussion 404. PubMed PMID: 20226919.
- Abbott DE, **Baker MS, Talamonti MS**. Neoadjuvant therapy for pancreatic cancer: a current review. *J Surg Oncol*. 2010 Mar 15;101(4):315-20. Review. PubMed PMID: 20187063.
- Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Hogg A, Julian PJ, Price PM, Stratford IJ, **Bloomer WD**, Papadopoulou MV, Williams KJ. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy. *Br J Cancer* 103:201-208, 2010.
- Papadopoulou MV, **Bloomer WD**, Torti VR, Page JG. IND-directed, five-day repeat dose toxicity study of NLCQ-1 (NSC 709257) administered with or without Taxol® in Sprague Dawley rats. *Basic & Clinical Pharmacology & Toxicology*, 106:497-504, 2010
- Papadopoulou MV, **Bloomer WD**, Torti VR, Page JG. IND-Directed Toxicology and Pharmacokinetic Study of NLCQ-1 (NSC 709257) in Beagle Dogs. *Basic & Clinical Pharmacology & Toxicology* 106:511-522, 2010.
- Fitchew PP, Wcislak SM, Lee C, Bergh A, **Brendler CB**, Stellmach VM, Crawford SE, Mavroudis CD, Cornwell ML, Doll JA. Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. *Lab Invest*. 2010 Jul;90(7):1078-90. Epub 2010 May 10. PubMed PMID: 20458281.
- Yu N, Kozlowski, JM, Park II, Chen L, Zhang Q, Xu D, Doll JA, Crawford SE, **Brendler CB**, and Lee C. Over-expression of transforming growth factor β_1 in malignant prostate cells is partly caused by a runaway of TGF- β_1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF- β_1 type I receptor. *Urology*, 2010 (In Press).
- Jayram G, Decastro GJ, Large, MC, Razmaria A, Zagaja GP, Shalhav AL, **Brendler CB**. Radical Prostatectomy in Patients with High-Risk Disease: A Comparison of Robotic and Open Techniques from a Single Center. *J Endourol.*, 2010 (In Press).
- Doll JA, Huang L, Chung C, Fitchew, PP, Abramson LP, Cornwell ML, **Brendler CB**, Stellmach VM, Maurice MJ, Cohn SL, Plunkett BA, Kessler J, Ameer GA, Crawford SE. Neural cells regulate anti-angiogenic signals to suppress tumor growth. *Nature*, submitted for publication, 2010.
- Brockstein B**, Vokes EE. Accelerated radiotherapy for HNSCC in developing countries. *Nature Review Clinical Oncology* 2010; 7:616-618.
- Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, **Brockstein B**, Lester EP, Salama JK, Dekker A, Williams R, Witt ME, Grushko TA, Dignam JJ, Lingen MW, Olopade OI, Vokes EE. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. *J Clin Oncol*. 2010 Jul 10;28(20):3336-43. Epub 2010 May 24. PubMed PMID: 20498391; PubMed Central PMCID: PMC2903330.
- Ciric I**, Zhao JC, Du H. Transsphenoidal Surgery for Cushing's Disease: Experience with 136 Patients. Submitted to *Neurosurgery*.
- Moran MS, **Goss D**, Haffty BG, Kaufman CS, **Winchester DP**. Quality measures, standards, and accreditation for breast centers in the United States. *Int J Radiat Oncol Biol Phys*. 2010 Jan 1;76(1):1-4. PubMed PMID: 20005450.
- Larson JD, **Gutowksi KA**, et al. The effect of electroacustimulation on post-operative nausea, vomiting and pain in the outpatient plastic surgery patients: A prospective, randomized, blinded clinical trial. *Plast Reconstr Surg*. 125: 989, 2010.
- Stacey DH, Warner JP, Duggal A, **Gutowksi KA**, Marcus BC. International interdisciplinary rhytidectomy survey. *Ann Plastic Surg*. 64: 370, 2010.
- Havas DA, **Gutowksi KA**, et al. Cosmetic use of botulinum toxin-A affects processing of emotional language. *Psychological Science* (In Press).
- Hanson, SE, **Gutowksi KA**. Primary T-cell lymphoma associated with breast implant capsule. *Plast Reconstr Surg*. 126: 39e, 2010.
- Sitzman TJ, **Gutowski KA**. Detection of vessel occlusion in free tissue transfers using interstitial glucose monitoring. *Plast Reconstr Surg*. 126: 71, 2010.
- Sitzman TJ, Hanson SE, Alsheik NH, Gentry LR, Doyle JF, **Gutowski KA**. Clinical criteria for obtaining maxillofacial CT in trauma patients. *Plast Reconstr Surg*. (In Press).
- Hanson SE, **Gutowski KA**, Hematti P. Clinical applications of mesenchymal stem cells in soft tissue augmentation. *Aesthetic Surg J*. (In Press).
- Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, **Hensing T**, Lacouture ME. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. *J Natl Cancer Inst*. 2010 Jan 6;102(1):47-53. Epub 2009 Dec 9. PubMed PMID: 20007525.
- Stinchcombe TE, Bradford DS, **Hensing TA**, LaRocca RV, Saleh M, Evans T, Bakri K, Socinski MA. A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. *Cancer Invest*. 2010 Feb;28(2):208-15. PubMed PMID: 19916742.
- Ough M, Velasco J, **Hieken TJ**. A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. *Am J Surg* 2010; (In Press).
- Hieken TJ**. Skin and Soft Tissue Tumors. *Rush University Review of Surgery*, 5thEd., Elsevier-Saunders, in press for 2010.
- Fusco C, Boll J, Jones JE, **Hieken TJ**. Accuracy and predictive value of diagnostic biopsy in cutaneous melanoma. *Ann Surg Oncol* 2010; 17(S1):S104.
- Bordoli S, Kukreja SK, Velasco J, **Hieken TJ**. The impact of metastatic lymph node ratio on survival in node-positive colon cancer. *Ann Surg Oncol* 2010; 17(S1):S88.
- Starnes SL, Reed MF, Meyer CA, Shipley RT, Jazieh AR, Pina EM, Redmond K, Huffman LC, Pandalai PK, **Howington JA**. Can lung cancer screening by computed tomography be effective in areas with endemic histoplasmosis? *J Thorac Cardiovasc Surg* 2010 Oct 6.
- Oi J, Nakayama K, Cardiff RD, Borowsky AD, **Kaul K**, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. *Cancer Cell* 2010 Jul 13;18(1):23-38. PubMed PMID: 20609350.
- Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, **Kaul K, Talamonti M**, Abrams RA, Levenson V. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. *Cancer* 2010 Apr 1;116(7):1674-80. PubMed PMID: 20143430.
- Bommi PV, Dimri M, Sahasrabudhe AA, **Khandekar JD**, Dimri GP. The polycarb group protein BMI1 is a transcriptional target of HDAC inhibitors. *Cell Cycle* 2010 Jul 21;9(13). [Epub ahead of print] PMID: 20543557
- Dimri M, Bommi PV, Sahasrabudhe AA, **Khandekar JD**, Dimri GP. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. *Carcinogenesis* 2010 Mar;31(3):489-95.
- Chlebowski R, Johnson K, Lane D, Pettinger M, Kooperberg C, Wactawski-Wende J, Rohan T, O'Sullivan M, Yasmeen S, Hiatt R, Shikany J, Vitolins M, **Khandekar J**, et al. 25-Hydroxyvitamin D Concentration, Vitamin D Intake and Joint Symptoms in Postmenopausal Women. *Maturitas* (submitted)
- Shankaran V, **Obel J**, Benson AB 3rd. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. *Oncologist*. 2010;15(2):157-67. Epub 2010 Feb 4. Review. PubMed PMID: 20133499.
- Shukla V, Coumoul X, Lahusen T, Wang RH, Xu X, Vassilopoulos A, Xiao C, Lee MH, Man YG, Ouchi M, **Ouchi T**, Deng CX. BRCA1 affects global DNA methylation through regulation of DNMT1. *Cell Res*. 2010 Sep 7. [Epub ahead of print] PMID: 20820192

Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, **Paleologos NA**, Patchell RA, Ryken TC, Kalkanis SN. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010 Jan;96(1):45-68. Epub 2009 Dec 4. Review. Erratum in: *J Neurooncol*. 2010 Jan;96(1):69-70. PubMed PMID: 19960227; PubMed Central PMCID: PMC2808519.

Ammirati M, Cobbs CS, Linskey ME, **Paleologos NA**, Ryken TC, Burri SH, Asher AL, Loeffler JS, Robinson PD, Andrews DW, Gaspar LE, Kondziolka D, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Patchell RA, Kalkanis SN. The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010 Jan;96(1):85-96. Epub 2009 Dec 3. Review. PubMed PMID: 19957016; PubMed Central PMCID: PMC2808530.

Mikkelsen T, **Paleologos NA**, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010 Jan;96(1):97-102. Epub 2009 Dec 3. Review. PubMed PMID: 19957015; PubMed Central PMCID: PMC2808526.

Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, **Paleologos NA**, Patchell RA, Kalkanis SN. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010 Jan;96(1):103-14. Epub 2009 Dec 3. Review. PubMed PMID: 19957014; PubMed Central PMCID: PMC2808527.

Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mikkelsen T, Olson JJ, **Paleologos NA**, Ryken TC, Kalkanis SN. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010 Jan;96(1):17-32. Epub 2009 Dec 4. Review. PubMed PMID: 19960231; PubMed Central PMCID: PMC2808517.

Olson JJ, **Paleologos NA**, Gaspar LE, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Patchell RA, Ryken TC, Kalkanis SN. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. *J Neurooncol*. 2010 Jan;96(1):115-42. Epub 2009 Dec 3. PubMed PMID: 19957013; PubMed Central PMCID: PMC2808529.

Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, Ammirati M, Robinson PD, Andrews DW, Loeffler JS, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, **Paleologos NA**, Patchell RA, Ryken TC, Linskey ME. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010 Jan;96(1):33-43. Epub 2009 Dec 4. Review. PubMed PMID: 19960230; PubMed Central PMCID: PMC2808516.

Mehta MP, **Paleologos NA**, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol*. 2010 Jan;96(1):71-83. Epub 2009 Dec 4. Review. PubMed PMID: 19960229; PubMed Central PMCID: PMC2808518.

Nelson KK, Gattuso P, Xu X, **Prinz RP**. Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy. *Surgery* 2010;148(4): 654-660

Weinberg LE, **Rodriguez G, Hurteau JA**. The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. *J Surg Oncol*. 2010 Mar 15;101(4):334-43. Review. PubMed PMID: 20187069.

Simon M, **Rosenberg C**, Rodabough R, Greenland P, Ockene I, **Roy H**, Lane D, Cauley J, **Khandekar J**. Prospective Analysis of Association between Use of Statins or Other Lipid Lowering Agents and Colorectal Cancer Risk. *JNCI* (submitted).

Roy HK, Gomes AJ, Ruderman S, Bianchi LK, Goldberg MJ, Stoyneva V, Rogers JD, Turzhitsky V, Kim Y, Yen E, Jameel M, Bogojevic A, Backman V. Optical measurement of rectal microvasculature as an adjunct to flexible sigmoidoscopy: gender-specific implications. *Cancer Prev Res (Phila Pa)*. 2010 Jul;3(7):844-.

Damania D, Subramanian H, Tiwari AK, Stypula Y, Kunte D, Pradhan P, **Roy HK**, Backman V. Role of cytoskeleton in controlling the disorder strength of cellular nanoscale architecture. *Biophys J*. 2010 Aug 4;99(3):989-96.

Roy HK, Subramanian H, Damania D, **Hensing T**, Rom W, Pass H, Ray D, Rogers J, Bogojevic A, Shah M, Kuzniar T, Pradhan P, Backman V. Biophotonic Detection of Buccal Epithelial Nano-Architectural Alterations in Patients Harboring Lung Cancer: Implications for Screening. *Cancer Res* (In Press).

Turzhitsky V, Gomes A, Kim Y, Liu Y, Kromine A, Rogers J, Jameel M, **Roy HK**, Backman V. Measuring Mucosal Blood Supply *in vivo* with a Polarization Gating Probe. *Applied Optics* (In Press).

Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, Evans DG, **Rubinstein W**, Singer CF, Rubin S, Lynch HT, Daly MB, Weitzel J, Ganz PA, Pichert G, Olopade OI, Tomlinson G, Tung N, Blum JL, Couch F, Rebbeck TR. Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. *Breast Cancer Res Treat*. 2010 Feb 24. [Epub ahead of print] PubMed PMID: 20180014

Mangold KA, Wang V, Weissman SM, **Rubinstein WS, Kaul KL**. Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences. *J Mol Diagn*. 2010 Jan;12(1):20-6. Epub 2009 Dec 3. PubMed PMID: 19959799; PubMed Central PMCID: PMC2797714.

Neuhausen SL, Brummel S, Ding YC, Singer C, Pfeiler G, Lynch HT, Nathanson KL, Rebbeck TR, Garber JE, Couch F, Weitzel J, Narod SA, Ganz PA, Daly MB, Godwin A, Isaacs C, Olopade OI, Tomlinson G, Rubinstein WS, Tung N, Blum JL, Gillen DL. Genetic Variation in Insulin-Like Growth Factor Signaling Genes and Breast Cancer Risk Among BRCA1 and BRCA2 Carriers. DOI:10.1186/bcr2414. *Breast Cancer Res*, 2009;11(5):R76.

Acheson LS, Wang C, Zyzanski S, Lynn A, Ruffin MT, Gramling R, **Rubinstein WS**, O'Neill SM, Nease DT for the Family Healthware Impact Trial (FHITr) Group. Family history and perceptions about risk and prevention for chronic diseases in primary care: a report from the Family Healthware Impact Trial (FHITr). DOI:10.1097/GIM.0b013e3181d56ae6. *Genet Med*, 2010;12(4):212-218.

Domchek SM, Friebel TM, Singer C, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, van t'Veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers with Cancer Risk and Mortality. *JAMA*, 2010; 304(9):967-975.

Rubinstein WS: Endocrine Cancer Predisposition Syndromes: Hereditary Paraganglioma, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, and Hereditary Thyroid Cancer. Robson M, Offit K (eds): DOI: 10.1016/j.hoc.2010.06.008. *Hematol Oncol Clin North Am*, 2010; 24(5): 907-937.

Mitra AV, Cybulski C, **Rubinstein WS**, Buys S, Townshend S, Eeles RA. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. *BJU International*. 2010. DOI: 10.1111/j.1464-410X.2010.09648.x.

Antoniou AC, Wang X, Soucy P, **Rubinstein, WS**, Arason A, Rennert G, Easton DF, Couch FJ. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet* 2010, doi:10.1038/ng.669.

Whitaker HC, Mercer C, **Rubinstein WS**, Clowes V, Easton D, The IMPACT Study Steering Committee, The IMPACT Study Collaborators, UK GPCS Collaborators, Cooper C, Eeles R, Neal DE. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. doi:10.1371/journal.pone.0013363. *PLoS ONE* 2010; 5(10): e13363.

Rubinstein WS, O'Neill SM, Rothrock N, Starzyk EJ, Beaumont J, Acheson LS, Wang C, Gramling R, Gallihier JM, Ruffin M, for the FHITr group. Components of family history associated with women's disease perceptions for cancer: a report from the Family Healthware™ Impact Trial. *Genet Med* 2011 (In Press).

Ruffin MT, Nease DE, Sen A, Pace WD, Wang C, Acheson LS, **Rubinstein WS**, O'Neill SM, Gramling R. for the Family History Impact Trial (FHITr) group. Effect of preventive messages tailored to family history on health behaviors: the Family Healthcare Impact Trial. *Ann Fam Med*, 2010 (In Press).

Nielsen SM, **Rubinstein WS**, Thull DL, Armstrong MJ, Feingold E, Stang MT, Gnarr JR, Carty SE. Genotype-Phenotype Correlations of Pheochromocytoma in Two Large von Hippel-Lindau (VHL) Type 2A Kindreds with Different Missense Mutations. *Am J Med Genet* 2010 (In Press).

Anderson MA, Zolotarevsky E, Sherman S, Shat O, Whitcomb DC, Lynch HT, Ghiorzo P, **Rubinstein WS**, Vogel KJ, Sasson A, Grizzle WE, Ketcham MA, Lee SY, Normolle D, Singh N, Mertens AN, Brand RE. Differential effects of alcohol dose and type on age of presentation in pancreatic cancer. Submitted, *JAMA*, 2010.

Hu, Z., Zhang, ZW, Guise, T, and **Seth, P** Systemic Delivery of an Oncolytic Adenovirus Expressing Soluble TGF β Receptor II-Fc Fusion Protein Can Inhibit Breast Cancer Bone Metastasis in a Mouse Model. *Hum Gene Ther* (Nov. 2010).

Hu, Z, Robbins, J.S, Pister, A, Zafar, MB, Gupta, J, Zhang, Z-W, Lee, KJ, Neuman, K, Yun, C-O, Guise, T, and **Seth, P**. A modified hTERT Promoter-directed Oncolytic Adenovirus Replication with Concurrent Inhibition of TGF β Signaling for Breast Cancer Therapy. *Cancer Gene Ther*. 17: 235-243, 2010.

Victorson DE, Beaumont JL, Rosenbloom SK, **Shevrin D, Cella D**. Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT-P Symptom Index. *Psychooncology*. 2010 Jul 25. [Epub ahead of print]PubMed PMID: 20661866.

Gupta S, Wang Y, Ramos-Garcia R, **Shevrin D**, Nelson JB, Wang Z. Inhibition of 5 α -reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. *Prostate*. 2010 Jun 16. [Epub ahead of print] PubMed PMID: 20564326.

Eton DT, **Shevrin DH**, Beaumont J, **Victorson D, Cella D**. Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer. *Value Health*. 2010 Mar 10. [Epub ahead of print] PubMed PMID: 20230544.

Wang Y, Gupta S, Hua V, Ramos-Garcia R, **Shevrin D**, Jovanovic BD, Nelson JB, Wang Z. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model. *Prostate*. 2010 Feb 1;70(2):147-54. PubMed PMID: 19739129; PubMed Central PMCID: PMC2805824.

Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, **Talamonti MS**, Iacobuzio-Donahue CA, Hollingsworth MA, Perou CM, Yeh JJ. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. *PLoS Med*. 2010 Jul 13;7(7):e1000307. PubMed PMID: 20644708; PubMed Central PMCID:PMC2903589.

Small W Jr, Mulcahy MF, Rademaker A, Bentrem DJ, Benson AB, Weitner BB, **Talamonti MS**. Phase II Trial of Full-dose Gemcitabine and Bevacizumab in Combination with Attenuated Three-dimensional Conformal Radiotherapy in Patients with Localized Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. 2010 Jun 30. [Epub ahead of print] PubMed PMID: 20598452.

Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, **Talamonti M**, Xu N, Cooper H, Benson AB 3rd. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. *J Surg Oncol*. 2010 Jun 1;101(7):587-92. PubMed PMID: 20461765.

Cao W, Adley BP, Liao J, Lin X, **Talamonti M**, Bentrem DJ, Rao SM, Yang GY. Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm. *Hum Pathol*. 2010 Apr;41(4):513-21. Epub 2009 Dec 1. PubMed PMID: 19954814; PubMed Central PMCID: PMC2838933.

Raval MV, Bilmoria KY, **Talamonti MS**. Quality improvement for pancreatic cancer care: is regionalization a feasible and effective mechanism? *Surg Oncol Clin N Am*. 2010 Apr;19(2):371-90. PubMed PMID: 20159520.

Bilmoria KY, Bentrem DJ, **Talamonti MS**, Stewart AK, **Winchester DP**, Ko CY. Risk-based selective referral for cancer surgery: a potential strategy to improve perioperative outcomes. *Ann Surg*. 2010 Apr;251(4):708-16. PubMed PMID: 19898231.

Cheon EC, Small W, Strouch MJ, Krantz SB, Rademaker A, Mulcahy MF, Benson AB, Bentrem DJ, **Talamonti MS**. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. *J Surg Oncol*. 2010.

Fronza J, Bentrem DB, Baker MS, **Talamonti M, Ujiki M**. Radiofrequency energy in laparoscopic distal pancreatectomy. *Am J Surg*. 2010 Mar;199(3):401-4.

Diwan TS, Martinec DV, **Ujiki MB**, Dunst CM, Swanstrom LL. A simplified technique for placement of biologic mesh in paraesophageal hernia repair (PEH). *Surg Endosc*. 2010 Jan;24(1):221-2.

Ujiki MB, Martinec DV, Diwan TS, Denk PM, Dunst CM, Swanstrom LL. Natural orifice transluminal endoscopic surgery (NOTES): creation of a gastric valve for safe and effective transgastric surgery in humans. *Surg Endosc*. 2010 Jan;24(1):220.

Roginsky AB, Ding XZ, Woodward C, **Ujiki MB**, Singh B, Bell RH, Collin P, Adrian TE. Anti-pancreatic cancer effects of a polar extract from the edible sea cucumber, *cucumaria frondosa*. *Pancreas*. 2010 Jul;39(5):646-52.

Heiferman MJ, Salabat MR, **Ujiki MB**, Strouch MJ, Cheon EC, Silverman RB, Bentrem DJ. Sansalvamide induces pancreatic cancer growth arrest through changes in the cell cycle. *Anticancer Res*. 2010 Jan;30(1):73-8.

Ujiki MB, Adler A, Swanstrom LL, Diwan TS, Hansen P. Emergent pancreaticoduodenectomy for Dieulafoy's lesion of the duodenum. *Am Surg*. 2010 Jun;76(6):656-7.

Cassera MA, Potter KW, **Ujiki MB**, Swanstrom LL, Hansen PD. Computed tomography (CT)-guided versus laparoscopic radiofrequency ablation: a single-institution comparison of morbidity rates and hospital costs. *Surg Endosc*. 2010 Sep.

Ough M, **Velasco J**, Hieken TJ. A comparative analysis of core needle biopsy and final excision for breast cancer: Histology and marker expression. *Am J Surg* 2010 (In Press).

Robertson LB, Davis F, **Vick NA**, Johansen C, Andersson U, Melin BS, Bondy ML, Houlston RS. Survey of familial glioma and role of germline p16 (INK4A) /p14 (ARF) and p53 mutation. *Fam Cancer*. 2010 May 9. [Epub ahead of print] PubMed PMID: 20455025.

Abbott DE, Margaryan NV, Jeruss JS, Khan S, Kaklamani V, **Winchester DJ**, Hansen N, Rademaker A, Khalkhali-Ellis Z, Hendrix MJ. Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. *Cancer Biol Ther*. 2010 Jan;9(1):23-30. Epub 2010 Jan 15. PubMed PMID: 19923884.

Melstrom LG, Melstrom KA, Wang EC, Pilewskie M, **Winchester DJ**. Ductal carcinoma in situ: size and resection volume predict margin status. *Am J Clin Oncol* 2010; 33(5):438-42.

Raval MV, Bilmoria KY, Bentrem DJ, Stewart AK, **Winchester DP**, Ko CY, Reynolds M. Nodal evaluation in Wilms' tumors: analysis of the national cancer data base. *Ann Surg*. 2010 Mar;251(3):559-65. PubMed PMID: 20083995.

Winchester DP, Stewart AK, Phillips JL, Ward EE. The national cancer data base: past, present, and future. *Ann Surg Oncol*. 2010 Jan;17(1):4-7. Epub 2009 Oct 22. PubMed PMID: 19847564; PubMed Central PMCID: PMC2805801

Winchester DP. Evaluating and managing breast disease in the United States: Are we properly organized? *Journal of Surgical Oncology* 102:299-300, 2010.

Yao K, Stewart AK, **Winchester DJ, Winchester DP**. Trends in contralateral prophylactic mastectomy for unilateral cancer: A report from the National Cancer Data Base, 1998-2007. *Ann Surg Oncol* 17:2554-2562, 2010.

Yao K, Rizzo P, Rajan P, Albain K, Rychlik K, Shah S, Miele L. Notch-1 and -4 receptors as prognostic markers in breast cancer. *International Journal of Surgical Pathology* 2010 May 5 (Epub ahead of print).

Cunningham DK, **Yao KA**, Turner RR, Singer FR, Van Herle AR, Giuliano AE. Sentinel Lymph Node Biopsy for Papillary Thyroid Cancer: 12 Years of Experience at a Single Institution. *Ann Surg Oncol*. 2010 Jun 15. [Epub ahead of print] PubMed PMID: 20552407.

Liu SV, Melstrom L, **Yao K**, Russell CA, Sener SF. Neoadjuvant therapy for breast cancer. *J Surg Oncol*. 2010 Mar 15;101(4):283-91. Review. PubMed PMID: 20187061.

continued >>

2010 ABSTRACTS

Papadopoulos MV, Bourdin B, **Bloomer WD**, Brun R, Kaiser M, Torreele E. Novel nitroaromatic heterocyclics as potential anti-trypanosomal drugs. II. *The 239th ACS National Meeting & Exposition*. San Francisco, CA, March 21-25 2010.

Carro G, Lawton J, Harper A, Palafox A. Evaluation of Elastomeric and Electronic Medication Pumps at an Outpatient Cancer Center. Poster presented at the Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting in 2010. Featured in *Pharmacy Practice News*, June 2010

Schiavo K, **Carro G**, Lawton J. Outpatient Oncology Treatment Center Approach to Enhancing Continuity of Care Related to Dispensing Oral Chemotherapeutic Agents. Poster presented at the Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting in 2010. Featured in *Pharmacy Practice News*, July 2010: "Outpatient Drug Service a Boon to Cancer Patients"

Komrokji R, List A, Sekeres M, Narang M, Swern A, Sullivan K, Street T, **Grinblatt D**. Azacitidine (AZA) Treatment Patterns, Hematologic Improvement, and Tolerability in a Large Group of Elderly Patients with Myelodysplastic Syndromes (MDS) in the AVIDA Registry Treated in a Community Setting. European Hematology Association Annual Meeting Abstract 538, Barcelona, Spain, June 2010.

Grinblatt D, Hui Y, Smith E, Kaminer L: Therapy Related MDS/AML Following Rituxan and Fludarabine in Waldenstrom's and Marginal Zone Lymphoma. International Society of Hematology World Congress, Oct 2010.

Sekeres M, Narang M, Komrokji R, Maciejewski J, List A, Street T, Swern A, Sullivan K and **Grinblatt D**. Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry Blood (ASH Annual Meeting Abstracts) 114: 2931, Nov 2010.

Stinchcombe T, Bradford DS, Lee CB, Moore Dt, Bakri KM, Taylor MA, Crane JM, Schwartz G, **Hensing TA**, Socinski MA. Preliminary results of a randomized phase II trial of first-time treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 28:15s, 2010 (suppl; abstr 7576).

Hensing TA, Fidler MJ, Wong F, Polish A, Watkin W, Basu S. Kaiser-Walters KA, Pool M, Coon J, Bonomi P. The association between PTEN expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 7552).

Shah NB, Fidler MJ, Walters KK, Braun E, Baus S, Harasty H, Coon J, Pool M, **Hensing TA**, Bonimi PD. Association of epithelial mesenchymal transition (EMT) markers and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 7550).

Stinchcombe T, Bradford DS, Lee CB, Moore DT, Bakri KM, Taylor MA, Crane JM, Schwartz G, **Hensing TA**, Socinski MA. Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 28:15s, 2010 (suppl; abstr 7576).

Menas P, **Merkel DE**, **Carro G**, Hui W, Lawton J, Harper A, Blankenship A. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. 2010 ASCO Breast Cancer Symposium, General Poster Session A, Abstract #218

Menas P, **Merkel D**, Hui W, **Carro G**, Lawton J, Blankenship A, Harper A. Management and monitoring of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. ASCO Abstract 2010.

Menas P, **Merkel D**, **Carro G**, Hui W, Lawton J, Harper A, Blankenship A. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. Poster presented at the ASCO Breast Cancer Symposium in 2010.

Menas P, **Merkel D**, **Carro G**, Lawton J, Harper A, Hui W, Blankenship A. Incidence and Management of Arthralgias in Breast Cancer Patients Treated with Aromatase Inhibitors in an Outpatient Oncology Clinic. Poster presented at the Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting in 2010.

Hardacre JM, Mulcahy MF, Talamonti M, **Obel JC**, Rocha Lima CS, Safran H, Rossi GR, Tennant L, Vahanian NN, Link CJ. Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 4059).

Lassman AB, Panageas KS, Iwamoto FM, DeAngelis LM, Rivera AL, Aldape KD, Cloughesy TF, Eichler A, Louis DN, **Paleologos NA**, et al. International Retrospective Study of 1,000 Adults With Anaplastic Oligodendroglial Tumors. *NeuroOncology*, October 2009; 629.

Lai R, Recht L, Reardon D, **Paleologos N**, Groves M, Rosenfeld M, Meech S, Davis T, Pavlov D, Sampson J. PF-04948568 (CDX-110) in Combination With Temozolomide (TMZ) in Patients (pts) With Glioblastoma (GBM). Poster Presentation at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2010.

Cloughesy T, Vredenburgh JJ, Day B, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, **Paleologos N**, Nicholas MK, Jensen R, Das A, Friedman HS. Updated Safety and Survival of Patients With Relapsed Glioblastoma Treated With Bevacizumab in the BRAIN Study. Presented at the American Society of Clinical Oncology Annual Meeting, Chicago, IL, June 2010.

Rubinstein W, O'Neill S, Beaumont J, Acheson L, Ruffin M, Wang C for the FHITr group. Clinical Utility of Family History for Cancer Screening and Referral: The Family Healthcare™ Impact Trial (FHITr). Presented to the 34th Annual American Society of Preventive Oncology (ASPO) Meeting in Bethesda, MD March 20-23, 2010.

Wang C, Sen A, Ruffin MT, Gramling RE, Rothrock N, Nease D, Acheson L, O'Neill SM, **Rubinstein WS**. The impact of family history assessment on disease risk perceptions: Results from the Family Healthcare™ Impact Trial (FHITr). Recognized as a Citation Abstract and presented as a poster at the 31st Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine, Seattle, WA, April 7-10-, 2010.

Vogel KJ, Olopade OI, Patrick-Miller L, Rudnick J, Sanchez-Johnsen L, Phillips J, Selkirk CG, Wells J, Jackson S, Du H, **Rubinstein WS**. Evaluating the use of film media to assist decision-making during BRCA genetic counseling. Presented as a poster at the National Society of Genetic Counselors Annual Education Conference, Dallas, TX, October 11-16, 2010.

Bretl AL, Vogel KJ, **Rubinstein WS**, O'Neill SO. Effect on referrals when using electronic medical records to store genetic information. Presented as a poster at the National Society of Genetic Counselors Annual Education Conference, Dallas, TX, October 11-16, 2010.

Bretl AL, Vogel KJ, **Rubinstein WS**, O'Neill SO. Family practice physicians' awareness and knowledge of the Genetic Information Non-discrimination Act (GINA). Presented as a platform presentation at the National Society of Genetic Counselors Annual Education Conference, Dallas, TX, October 11-16, 2010.

Rubinstein WS, O'Neill SM, Rothrock N, Starzyk EJ, Beaumont JL, Gramling R, Gallher JM, Acheson LS, Wang C, Ruffin IV MT for the FHITr group. Components of family history associated with women's disease perceptions for cancer: a report from the Family Healthcare Impact Trial. Accepted as a platform presentation at the National Society of Human Genetics 60th Annual Meeting, Washington, DC, November 4, 2010.

Rubinstein WS, Zou C, Koneru RH, Vogel K, Wang V, Kaul K, Brand RE, Gao Q. Germline Mutations of Centromere Gene Likely Predispose Patients to Pancreatic Cancer. Accepted for a poster presentation at the 41st Annual Meeting of the American Pancreatic Association, Chicago, IL, November 3-6, 2010.

Schiavo, K. *Oral Chemotherapy: Overcoming the Challenges*. Presented at the ECOG Annual Meeting in 2010.